Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this open-label, flexible dose study is to assess the safety and
efficacy of pramipexole over a 24-week period in children and adolescents (age 6-17 years
inclusive) diagnosed with Tourette Syndrome according to Diagnostic and Statistical Manual of
Mental Disorders, 4th Edition (DSM-IV) criteria and who have completed either Study 248.641
(NCT 00681863) or 248.644 (NCT 00558467).